UY29991A1 - Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea - Google Patents

Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea

Info

Publication number
UY29991A1
UY29991A1 UY29991A UY29991A UY29991A1 UY 29991 A1 UY29991 A1 UY 29991A1 UY 29991 A UY29991 A UY 29991A UY 29991 A UY29991 A UY 29991A UY 29991 A1 UY29991 A1 UY 29991A1
Authority
UY
Uruguay
Prior art keywords
phenil
promarms
isopropil
pirimidin
metoxi
Prior art date
Application number
UY29991A
Other languages
English (en)
Inventor
Franzanne Vreeland
Ravi Mysore Shanker
Douglas Alan Lorenz
Susan Deborah Lagreca
Feng Gluo
Tracy Lee Boyden
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY29991A1 publication Critical patent/UY29991A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La invención se refiere a compuestos de la fórmula o una sal farmacéuticamente aceptable, profármaco o hidratos de los mismos. La invención también se refiere a composiciones farmacéuticas que contienen los compuestos de fórmula 1 y a métodos para tratar trastornos hiperproliferativos en un mamífero por medio de la ad ministración de los compuestos de fórmula 1.
UY29991A 2005-12-09 2006-12-06 Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea UY29991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74907005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
UY29991A1 true UY29991A1 (es) 2007-07-31

Family

ID=38123252

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29991A UY29991A1 (es) 2005-12-09 2006-12-06 Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea

Country Status (8)

Country Link
AR (1) AR058293A1 (es)
DO (1) DOP2006000271A (es)
GT (1) GT200600496A (es)
NL (1) NL2000337A1 (es)
PE (1) PE20071037A1 (es)
TW (1) TW200733965A (es)
UY (1) UY29991A1 (es)
WO (1) WO2007066189A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2699301A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
CL2008003092A1 (es) * 2007-10-19 2009-11-27 Abbott Gmbh & Co Kg Producto de dispersion solida que comprende a una agente activo derivado de n-aril urea, un agente formador de matriz seleccionado entre ciclodextrinas, polimeros, lipidos y un tensioactivo no ionico; proceso de preparacion de dicho producto de dispersion; y forma dosificacion farmaceutica que lo comprende .
EP2358720B1 (en) * 2008-10-16 2016-03-02 The Regents of The University of California Fused ring heteroaryl kinase inhibitors
KR20120124428A (ko) 2009-12-30 2012-11-13 아르퀼 인코포레이티드 치환된 피롤로-아미노피리미딘 화합물
WO2011163090A1 (en) * 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
BR112015006828A8 (pt) 2012-09-26 2019-09-17 Univ California composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN107722012B (zh) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives

Also Published As

Publication number Publication date
TW200733965A (en) 2007-09-16
GT200600496A (es) 2007-07-17
NL2000337A1 (nl) 2007-06-12
WO2007066189A3 (en) 2008-08-14
PE20071037A1 (es) 2007-11-19
AR058293A1 (es) 2008-01-30
WO2007066189A2 (en) 2007-06-14
DOP2006000271A (es) 2007-08-15

Similar Documents

Publication Publication Date Title
UY29991A1 (es) Sales, profármacos y formulaciones de 1-(5-(4-amino-7-isopropil-7h-pirrolo(2,3-d)pirimidin-5-carbonil)-2-metoxi-fenil)-3-(2,4-dicloro-fenil)-urea
ECSP055867A (es) Derivados de pirrolopirimidina
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
UY29322A1 (es) Inhibidores de cxcr2
CR10027A (es) Nuevos derivados de pirrol fusionado
ECSP014097A (es) Derivados de tiofeno utiles como agentes anticancerosos
CR10636A (es) Inhibidor de quinasa
CR10710A (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
ECSP099663A (es) Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y métodos para utilizar la misma
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
UY30460A1 (es) Compuestos terapéuticos
AR049681A1 (es) Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161213